{"author": "Zur, AA ", "adress": "BioLineRx Ltd, Modiin Maccabim Reut, Israel", "emails": ["arikz@biolinerx.com"], "title": "AGI-134: a fully synthetic alpha-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models"}